Full text is available at the source.
JAMA internal medicine···
Oral Semaglutide in East Asian Adults with Overweight or Obesity, With or Without Type 2 Diabetes
Updated
Abstract
Participants receiving oral semaglutide, 50 mg, experienced a 14.3% reduction in body weight compared to a 1.3% reduction in those on placebo.
- A total of 201 participants were randomized, with 134 receiving semaglutide and 67 receiving placebo.
- 84.3% of those on semaglutide achieved a weight reduction of 5% or more, compared to 17.2% on placebo.
- Gastrointestinal adverse events were reported in 63.4% of participants taking semaglutide versus 34.8% in the placebo group.
- Treatment discontinuation due to adverse events occurred in 4.5% of participants in the semaglutide group.
Simplified
IMPORTANCE: The efficacy and safety of oral semaglutide, 50 mg, in an East Asian population that also includes individuals with type 2 diabetes (T2D), who are prone to weight-related complications at lower body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) thresholds than other ethnic groups, is currently unknown.
OBJECTIVE: To assess the efficacy and safety of once-daily oral semaglutide, 50 mg, for the treatment of overweight and obesity in East Asian individuals with or without T2D.
DESIGN, SETTING, AND PARTICIPANTS: The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea. Adults with a BMI of 27.0 or greater with 2 or more related complications or a BMI of 35.0 or greater with 1 or more related complications were enrolled. Approximately 25% of participants were planned to have T2D at screening. Data were analyzed from March 2022 to July 2025.
INTERVENTIONS: Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.
MAIN OUTCOMES AND MEASURES: The coprimary end points were percentage change in body weight from baseline and the proportion of participants who achieved 5% or greater body weight reductions. Changes in physical function, cardiometabolic risk factors, and safety were also evaluated.
RESULTS: Overall, 201 participants (mean [SD] age, 49 [11] years; mean [SD] body weight, 91.9 [18.2] kg; 87 [43.3%] female; 51 [25.4%] with T2D) were randomized to semaglutide (n = 134) or placebo (n = 67). The mean (SEM) percentage change in body weight was -14.3% (0.8) with semaglutide vs -1.3% (1.1) with placebo (estimated treatment difference, -13.07 percentage points; 95% CI, -15.61 to -10.52; P < .001). More participants had 5% or greater body weight reductions with semaglutide vs placebo (107 of 127 [84.3%] vs 11 of 64 [17.2%]; odds ratio, 23.00; 95% CI, 10.28-51.42; P < .001). Gastrointestinal tract adverse events were reported by 85 of 134 participants (63.4%) with semaglutide and 23 of 66 with placebo (34.8%). Adverse events led to treatment discontinuation in 6 of 134 participants (4.5%) in the semaglutide arm.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without T2D, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction in body weight compared with placebo, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist class.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05132088.
Related papers
Feb '22
Weekly Semaglutide for Weight Loss in East Asian Adults With or Without Type 2 Diabetes
top 1% journal
cited by 288 papers
randomized controlled trial
Jan '22
Weekly Semaglutide Compared to Daily Liraglutide for Weight Loss in Adults with Overweight or Obesity Without Diabetes
top 1% journal
cited by 821 papers
randomized controlled trial
Mar '21
Weekly Semaglutide 2.4 mg for Adults with Overweight or Obesity and Type 2 Diabetes: A Controlled Clinical Trial
top 1% journal
cited by 1,112 papers
randomized controlled trial
Feb '21
Semaglutide compared to placebo with behavioral therapy for weight loss in adults with overweight or obesity
cited by 923 papers
randomized controlled trial
Mar '21
Continued weekly semaglutide helps maintain weight loss in adults with overweight or obesity compared to placebo
top 1% journal
cited by 1,124 papers
randomized controlled trial
Feb '21
Weekly Semaglutide treatment for adults with overweight or obesity
🏆 top 0.1% journal
cited by 4,102 papers
randomized controlled trial
Sep '25
Effects of 25 mg Oral Semaglutide in Adults with Overweight or Obesity
🏆 top 0.1% journal
cited by 39 papers
randomized controlled trial
Mar '25
Effectiveness and safety of weekly semaglutide 2.4 mg for weight loss in people from China
top 5% journal
cited by 2 papers
randomized controlled trial
Feb '24
Effectiveness and safety of weekly semaglutide 2.4 mg for weight loss in mostly East Asian adults with overweight or obesity
top 1% journal
cited by 101 papers
randomized controlled trial
Jun '23
Daily 50 mg oral semaglutide for adults with overweight or obesity: a randomized, placebo-controlled phase 3 trial
top 1% journal
cited by 328 papers
randomized controlled trial